<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062421</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-FME-2020-01</org_study_id>
    <nct_id>NCT05062421</nct_id>
  </id_info>
  <brief_title>Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.</brief_title>
  <acronym>Arthritis</acronym>
  <official_title>Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One-center observational study aimed at determining the survival of patients with rheumatoid&#xD;
      arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic&#xD;
      disease-modifying drugs (FAMEb).&#xD;
&#xD;
      These patients will be administered a series of medications and a follow-up will be carried&#xD;
      out to analyze their evolution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One-center observational study aimed at determining the survival of patients with rheumatoid&#xD;
      arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic&#xD;
      disease-modifying drugs (FAMEb).&#xD;
&#xD;
      The drugs to be administered to patients are:&#xD;
&#xD;
        -  JAK-type kinase inhibitors.&#xD;
&#xD;
        -  Monoclonal antibodies against TNF.&#xD;
&#xD;
        -  Soluble receptor against TNF.&#xD;
&#xD;
        -  Biosimilar FAMEb.&#xD;
&#xD;
        -  Rituximab.&#xD;
&#xD;
        -  Abatacept.&#xD;
&#xD;
        -  Drugs that block IL6.&#xD;
&#xD;
      A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of&#xD;
      treatment, to analyze how the patient's health improves.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival study</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>To know the survival at 12, 24, 48, 60, 72 and 84 months to the synthetic directed anti-rheumatic drugs, disease modifiers (FAMEsd) and the biological disease modifying anti-rheumatic drugs (FAMEb) in patients with rheumatoid arthritis treated in routine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of clinical characteristics.</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>To know the sociodemographic and clinical characteristics of the patients who receive FAMEsd and FAMEb in routine clinical practice at the HUVM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the influence of comorbidities.</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>To assess the influence of comorbidities on drug persistence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who discontinued treatment due to serious adverse effects.</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>Failure due to serious adverse events, adverse events of special interest, emerging adverse events and minor adverse events that require discontinuation of the drug.</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Cases 1</arm_group_label>
    <description>Patients treated with JAK-type kinase inhibitors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases 2</arm_group_label>
    <description>Patients treated with monoclonal antibodies against TNF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases 3</arm_group_label>
    <description>Patients treated with soluble receptor against TNF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases 4</arm_group_label>
    <description>Patients treated with FAME group biosimilars.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases 5</arm_group_label>
    <description>Patients treated with rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases 6</arm_group_label>
    <description>Patients treated with abatacept.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases 7</arm_group_label>
    <description>Patients treated with drugs that block the IL6.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged &gt; 18 years diagnosed with rheumatoid arthritis, who have been under treatment&#xD;
        with at least one dose of the study drugs, whose treatment is followed by the rheumatology&#xD;
        unit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥18 years.&#xD;
&#xD;
          -  With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR&#xD;
             criteria.&#xD;
&#xD;
          -  Who have received at least one of the doses of the study drugs.&#xD;
&#xD;
          -  In follow-up in the consultations of the UGC of Rheumatology of the HUVM.&#xD;
&#xD;
          -  With at least two complete evaluations (baseline and final) of clinical variables.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients where the medical records lack sufficient baseline and final variables to&#xD;
             perform the analysis.&#xD;
&#xD;
          -  Patients in whom more than 50% of the variables to be collected are missing in the&#xD;
             data collection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blanca Estela Hernández Cruz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blanca Estela Hernández Cruz</last_name>
    <phone>955008000</phone>
    <email>blancahcruz@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Pérez</last_name>
    <phone>955 04 31 27</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Estela Hernández Cruz</last_name>
      <phone>955008000</phone>
      <email>blancahcruz@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

